Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles received, Cumulative dose Intensity, and Survival in Resected Early-Stage Pancreas Cancer.

Patients with PDAC who received ≥67% of recommended chemotherapy cycles or ≥56% cumulative RDI had improved OS. Neoadjuvant therapy was associated with increased odds of receiving ≥67% of cycles and ≥56% cumulative RDI and should be considered in all patients with resectable PDAC.